References
1. Leibel SA, Scot CD, Loeffler JS. Conrtemporary approaches to the treatment of malignant gliomas with radiation therapy. Sem Oncol 1994; 21:198-219
2. Devita VT, Hellman S, Rosenberg SA. Cancer principles and practice of oncology. 5th Edition, Lippincort Raven; 1997;2023
3. Baltuch G, Couldwell WT, et al. Protein kinase C inhibitors suppress cell growth in established and low passage from glial cell lines. A comparison between staurosporine and Tamoxifen. Neurosurgery. 1993;33:495-501
4. Couldwell WT, Antel JP,et al. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas. Part II. Effects of glioma mitogens and modulators of PKC. Neurosurgery. 1992;31:714-724
5. Couldwell WT, Uhm J et al. Enhanced protein kinase in C activity correlates with the growth rate of malignant human gliomas. Neurosurgery. 1991;29:880-887
6. Nishizuka Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science (Washington DC) 1992; 252:607-614
7. O’Brian CA, Liskamp RM et al. Inhibition of protein kinase C by Tamoxifen. Cancer Res.1985;45:2462-2465
8. Pollack IF, Randall MS et al. Effect of Tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res. 1990;50:7134-7138
9. Vertosik FT, Selker RG et al. The treatment of intracranial gliomas using orally administered Tamoxifen therapy. Preliminary results in a series of failed patients. Neurosurgery. 1992;30:897-903
10. Couldwell WT, Hinton DR et al. Protein Kinase C inhibitors induce apoptosis in human malignant glioma lines. FEBS Letters. 1994;345:43-46
11. Robins HI, Peterson CG, Mehta MP. Combined modality treatment for central nervous system malignancies. Semin Oncol. 2003;30 (suppl. 9):11–22.
12. Baltuch GH, Dooley NP, Villemure JG, Yong VW. Protein kinase C and growth regulation of malignant gliomas. Can J Neurol Sci. 1995;22:264–271
13. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol. 1997; 24(suppl.):S1-65–S1-70.
14. Chmura SJ, Mauceri HJ, Advani S, Heimann R, Beckett MA, Nodzenski E, Quintans J, Kufe DW, Weichselbaum RR. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumour killing by ionizing radiation. Cancer Res. 1997;57:4340–4347
15. Mastronardi L, Puzzilli F, Couldwell WT, Farah JO, Lunardi P. Tamoxifen and carboplatin combinational treatment of high-grade gliomas: Results of a clinical trial on newly diagnosed patients. J Neuro Oncol. 1998b;38:59–68
16. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo ML, Masri L, Law RE, Weiss MH. Treatment of recurrent malignant gliomas with chronic oral high-dose Tamoxifen. Clin Cancer Res. 1996;2:619–622
17. Chang SM, Barker FG, II, Huhn SL, Nicholas MK, Page M, Rabbitt J, Prados MD. High dose oral Tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neurooncol. 1998;37:169–176.
18. Pollack IF, DaRosso RC, Robertson PL, Jakacki RL, Mirro JR, Jr, Blatt J, Nicholson S, Packer RJ, Allen JC, Cisneros A, Jordan VC. A phase I study of high-dose Tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res. 1997;3:1109–1115.
19. Gabriel Lacob et al. Current data and strategy in glioblastoma multiforme. Journal of Medicine and Life 2009; 2 (4) 386-393
20. Alberto Broniscer et al. Radiation Therapy and High-Dose Tamoxifen in the Treatment of Patients With Diffuse Brainstem Gliomas. Results of a Brazilian Cooperative Study. J Clin Oncol;2000:18(6):1246-1253
21. Alexander M et al. Phase II Study of Concurrent Continuous Temozolomide (TMZ) and Tamoxifen (TMX) for Recurrent Malignant Astrocytic Gliomas. J Neuro Oncology.2004;70(1):91-95
22. Muanza T, Shenouda G, Souhami L, Leblanc R, Mohr G, Corns R, Langleben A. High dose Tamoxifen and radiotherapy in patients with glioblastoma multiforme: A phase IB study. Can J Neurol Sci. 2000;27:302–306.
23. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and Tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17:2659-69.
24. Nayfield SG et al. Tamoxifen-associated eye disease, a review. J Clini Oncol. 1996; 14(3):1018-1026.
25. Ahemed T et al. Phase II trial of thalidomide (TD), Tamoxifen (TX), and Temozolomide (T) for patients with advanced malignant gliomas (MG). Journal of Clinical Oncology 2005; 23(16):1575-1575.
26. Rabbani G et al. Combination therapy with thalidomide, Temozolomide and Tamoxifen improves quality of life in patients with malignant astrocytomas. Anticancer Res. 2007; 27(4C):2729-36
27. Patel S et al. Phase I clinical trial assessing Temozolamide and Tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. Int J Radiat Oncol Biol Phys. 2012; 82(2):739-42.
DOI: https://dx.doi.org/10.18535/jmscr/v5i5.137
